Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase II Study

N. Nora Bennani, Pamela Atherton, Kimberly O Steinert, Lisa M. Rimsza, Aung M. Tun, Marc S. Hoffmann, Mayur S. Narkhede, Rakhee Vaidya, Rabih Said, Geoffrey I Shapiro, Brian A Costello, Stephen M Ansell, Grzegorz S. Nowakowski

Blood (2023) 142 (Supplement 1): 4475.

https://doi.org/10.1182/blood-2023-190540

Published: 2023

Journal Articles

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood (2021) 138 (Supplement 1): 165.

https://doi.org/10.1182/blood-2021-145764

Published: 2021

Journal Articles

First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019)

Liana Nikolaenko, Carolyn Mulroney, Peter A. Riedell, Ian W. Flinn, Jose Carlos Cruz, Rakhee Vaidya, Koen van Besien, Michael Emde, Vadim Klyushnichenko, Jonathan Strauss, Eduardo Laborda, Jing Li, Mohit Trikha, Peter G. Schultz, Travis S Young

Blood (2021) 138 (Supplement 1): 2822.

https://doi.org/10.1182/blood-2021-151727

Published: 2021

Journal Articles

Devimistat in Combination with Bendamustine Potently Inhibits Tumor Growth and Promotes CD8+ T Cell Tumor Infiltration in a Syngeneic Mouse Model of CD30+ T-Cell Lymphoma

Enzo Palma, Ashley Ballard, Elizabeth Forbes, Rakhee Vaidya, Bayard L. Powell, Qianqian Song, Wei Zhang, Timothy S. Pardee

Blood (2021) 138 (Supplement 1): 2263.

https://doi.org/10.1182/blood-2021-149243

Published: 2021

Journal Articles

Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Zanetta S. Lamar, MD, Scott Isom, MS, Rakhee Vaidya, MD, Anne W Beaven, MD, Zachariah A. McIver, DO

Blood (2016) 128 (22): 4163.

https://doi.org/10.1182/blood.V128.22.4163.4163

Published: 2016

Journal Articles

Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements"

Ellen D. McPhail, MD, Matthew J Maurer, MS, Rhett P. Ketterling, MD, William R. Macon, MD, Andrew L Feldman, MD, Paul J Kurtin, MD, Thomas E. Witzig, MD, Rakhee Vaidya, MD, Thomas M. Habermann, MD

Blood (2016) 128 (22): 1750.

https://doi.org/10.1182/blood.V128.22.1750.1750

Published: 2016

Journal Articles

Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas)

Thomas M. Habermann, MD, William R. Macon, MD, Matthew J Maurer, MS, Rhett P. Ketterling, MD, Paul J Kurtin, MD, Andrew L Feldman, MD, Rakhee Vaidya, MD, James R Cerhan, MD PhD, Stephen Ansell, MD PhD, Luis Porrata, MD, Grzegorz S. Nowakowski, MD, Thomas E. Witzig, MD, Ellen D. McPhail, MD

Blood (2016) 128 (22): 155.

https://doi.org/10.1182/blood.V128.22.155.155

Published: 2016

Journal Articles

Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.

Guido Finazzi, MD, Elisa Rumi, MD, Alessandro M. Vannucchi, MD, Maria Luigia Randi, Ilaria Nichele, Heinz Gisslinger, MD, Rakhee Vaidya, MD, Mario Cazzola, Alessandro Rambaldi, MD, Lisa Pieri, MD, Francesco Rodeghiero, MD, Animesh Pardanani, MBBS, PhD, Juergen Thiele, Francesco Passamonti, MD, T Barbui, Ayalew Tefferi, MD

Blood (2012) 120 (21): 2849.

https://doi.org/10.1182/blood.V120.21.2849.2849

Published: 2012

Journal Articles

Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,

Rakhee Vaidya, MD, Nanna Sulai, Shaina A Rozell, MD, Sania S Raza, MD, Sameer Parikh, MD, Thitina Jimma, MD, Christy Finke, BS, Terra L Lasho, MT, (ASCP), Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3850.

https://doi.org/10.1182/blood.V118.21.3850.3850

Published: 2011

Journal Articles

Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases

Ayalew Tefferi, MD, Naseema Gangat, MD, Rakhee Vaidya, MD, Kebede Begna, MD, Curtis A. Hanson, MD, Daniel L. Van Dyke, Ph.D., Domenica Caramazza, Animesh Pardanani, MBBS, PhD

Blood (2011) 118 (21): 2806.

https://doi.org/10.1182/blood.V118.21.2806.2806

Published: 2011

Journal Articles

Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study

Ayalew Tefferi, MD, Elisa Rumi, Guido Finazzi, MD, Alessandro M. Vannucchi, MD, Maria Luigia Randi, Ilaria Nichele, Heinz Gisslinger, MD, Rakhee Vaidya, MD, Mario Cazzola, Alessandro Rambaldi, Lisa Pieri, MD, Francesco Rodeghiero, MD, Irene Bertozzi, Bettina Gisslinger, Animesh Pardanani, MBBS, PhD, Juergen Thiele, Francesco Passamonti, MD, Tiziano Barbui, MD

Blood (2011) 118 (21): 277.

https://doi.org/10.1182/blood.V118.21.277.277

Published: 2011

Journal Articles

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients

Ayalew Tefferi, Thitina Jimma, Naseema Gangat, Rakhee Vaidya, Kebede H. Begna, Curtis A. Hanson, Daniel L. Van Dyke, Domenica Caramazza, Animesh Pardanani

Blood (2011) 118 (17): 4595–4598.

https://doi.org/10.1182/blood-2011-08-371096

Published: 2011

Includes: Supplemental data

Journal Articles

Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival

Rakhee Vaidya, Domenica Caramazza, Kebede H. Begna, Naseema Gangat, Daniel L. Van Dyke, Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi

Blood (2011) 117 (21): 5612–5615.

https://doi.org/10.1182/blood-2010-11-320002

Published: 2011

Includes: Supplemental data

Journal Articles

DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status

Naseema Gangat, MD, Domenica Caramazza, MD, Rakhee Vaidya, Geeta George, PA, Kebede Begna, MD, Susan Schwager, Daniel L. Van Dyke, PhD, Curtis Hanson, MD, Wenting Wu, PhD, Animesh Pardanani, MBBS, Phd, Francisco Cervantes, MD, Francesco Passamonti, MD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 4104.

https://doi.org/10.1182/blood.V116.21.4104.4104

Published: 2010

Journal Articles

Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients

Domenica Caramazza, Kebede Begna, MD, Naseema Gangat, M.D., Rakhee Vaidya, Sergio Siragusa, MD, Daniel L. Van Dyke, PhD, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 4122.

https://doi.org/10.1182/blood.V116.21.4122.4122

Published: 2010

Journal Articles

Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

Rakhee Vaidya, Domenica Caramazza, Christy Finke, Terra Lasho, MT, (ASCP), Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 3068.

https://doi.org/10.1182/blood.V116.21.3068.3068

Published: 2010

Journal Articles

Monosomal Karyotype In Primary Myelofibrosis Is Prognostically Worse Than Otherwise Unfavorable Karyotype

Rakhee Vaidya, Domenica Caramazza, Kebede Begna, MD, Naseema Gangat, M.D., Daniel L. Van Dyke, PhD, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 3069.

https://doi.org/10.1182/blood.V116.21.3069.3069

Published: 2010

Journal Articles

Long-Term Survival Data in 652 Patients with Primary Myelofibrosis or Polycythemia Vera— Trends in Recent Years.

Rakhee Vaidya, Naseema Gangat, MD, Sergio Siragusa, MD, Susan Schwager, Curtis A. Hanson, MD, Michelle Elliott, MB, BCh, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 2910.

https://doi.org/10.1182/blood.V114.22.2910.2910

Published: 2009

Journal Articles

Hydroxyurea Effect On Marked Splenomegaly Associated with Primary Myelofibrosis: Response Rates and Correlation with JAK2 V617F Allele Burden.

Sergio Siragusa, MD, Rakhee Vaidya, Ayalew Tefferi, MD

Blood (2009) 114 (22): 4971.

https://doi.org/10.1182/blood.V114.22.4971.4971

Published: 2009

Journal Articles

Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status.

Ayalew Tefferi, MD, Sergio Siragusa, MD, Rakhee Vaidya, Susan Schwager, Kebede Hussein, MD, Curtis A. Hanson, MD, Animesh D. Pardanani, MBBS, PhD, Francisco Cervantes, Francesco Passamonti

Blood (2009) 114 (22): 1909.

https://doi.org/10.1182/blood.V114.22.1909.1909

Published: 2009

NARROW

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase II Study

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019)

Devimistat in Combination with Bendamustine Potently Inhibits Tumor Growth and Promotes CD8+ T Cell Tumor Infiltration in a Syngeneic Mouse Model of CD30+ T-Cell Lymphoma

Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements"

Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas)

Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.

Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,

Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases

Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients

Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival

DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status

Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients

Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

Monosomal Karyotype In Primary Myelofibrosis Is Prognostically Worse Than Otherwise Unfavorable Karyotype

Long-Term Survival Data in 652 Patients with Primary Myelofibrosis or Polycythemia Vera— Trends in Recent Years.

Hydroxyurea Effect On Marked Splenomegaly Associated with Primary Myelofibrosis: Response Rates and Correlation with JAK2 V617F Allele Burden.

Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only